Mark Bloch

2.6k total citations
40 papers, 1.5k citations indexed

About

Mark Bloch is a scholar working on Infectious Diseases, Emergency Medicine and Epidemiology. According to data from OpenAlex, Mark Bloch has authored 40 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 11 papers in Emergency Medicine and 9 papers in Epidemiology. Recurrent topics in Mark Bloch's work include HIV/AIDS drug development and treatment (11 papers), HIV-related health complications and treatments (11 papers) and HIV Research and Treatment (7 papers). Mark Bloch is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), HIV-related health complications and treatments (11 papers) and HIV Research and Treatment (7 papers). Mark Bloch collaborates with scholars based in Australia, United States and France. Mark Bloch's co-authors include Janaki Amin, Andrew Carr, Sean Emery, Allison Martin, Naomi Schlesinger, Alexander So, Gerhard Krammer, Thomas Bardin, Alberto Gimona and V. Murphy and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Journal of Allergy and Clinical Immunology.

In The Last Decade

Mark Bloch

36 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Bloch Australia	17	669	481	391	351	306	40	1.5k
Sonia Rodríguez‐Nóvoa Spain	26	1.5k 2.3×	532 1.1×	745 1.9×	689 2.0×	549 1.8×	72	2.2k
Tejinder S. Ahuja United States	20	812 1.2×	551 1.1×	207 0.5×	336 1.0×	131 0.4×	35	1.4k
T. K. Sreepada Rao United States	15	544 0.8×	319 0.7×	209 0.5×	241 0.7×	73 0.2×	27	1.2k
Jen-Tse Cheng United States	14	321 0.5×	249 0.5×	113 0.3×	152 0.4×	117 0.4×	28	1.0k
Javier Szwarcberg United States	18	1.4k 2.1×	417 0.9×	1.0k 2.6×	453 1.3×	97 0.3×	48	4.1k
Jean‐Paul Viard France	20	654 1.0×	413 0.9×	293 0.7×	352 1.0×	76 0.2×	39	1.3k
Xuelian Wei United States	17	1.6k 2.4×	886 1.8×	1.0k 2.6×	254 0.7×	113 0.4×	33	2.0k
Eugenia Vispo Spain	31	1.1k 1.7×	472 1.0×	489 1.3×	1.8k 5.0×	1.9k 6.2×	104	2.9k
Antonio Guasch United States	16	548 0.8×	161 0.3×	53 0.1×	187 0.5×	48 0.2×	24	1.7k
Wolfgang Stöhr United Kingdom	22	889 1.3×	348 0.7×	691 1.8×	282 0.8×	23 0.1×	65	1.6k

Countries citing papers authored by Mark Bloch

Since Specialization

Citations

This map shows the geographic impact of Mark Bloch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bloch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bloch more than expected).

Fields of papers citing papers by Mark Bloch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bloch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bloch. The network helps show where Mark Bloch may publish in the future.

Co-authorship network of co-authors of Mark Bloch

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bloch. A scholar is included among the top collaborators of Mark Bloch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bloch. Mark Bloch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poynten, I. Mary, Richard Turner, Rick Varma, et al.. (2025). Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV. HIV Medicine. 26(12). 1930–1938.

Traeger, Michael W., Rebecca Guy, Eric P. F. Chow, et al.. (2024). Syphilis testing, incidence, and reinfection among gay and bisexual men in Australia over a decade spanning HIV PrEP implementation: an analysis of surveillance data from 2012 to 2022. The Lancet Regional Health - Western Pacific. 51. 101175–101175. 3 indexed citations

Sacks‐Davis, Rachel, Michael W. Traeger, Daniela K van Santen, et al.. (2024). Annual hepatitis C testing and positive tests among gay and bisexual men in Australia from 2016 to 2022: a serial cross-sectional analysis of sentinel surveillance data. Sexually Transmitted Infections. 100(5). 295–301. 1 indexed citations

Henderson, Samuel T., et al.. (2024). Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study. Journal of the Neurological Sciences. 464. 123147–123147. 1 indexed citations

Han, Win Min, Hossain M. S. Sazzad, Mark Bloch, et al.. (2024). Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study. Cell Reports Medicine. 5(12). 101835–101835.

Martinello, Marianne, Jeffrey J. Post, Robert Finlayson, et al.. (2024). Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023). Open Forum Infectious Diseases. 11(12). ofae665–ofae665. 1 indexed citations

Boettiger, David, Md Hamidul Huque, Mark Bloch, et al.. (2022). Physical function limitation among gay and bisexual men aged ≥55 years with and without HIV: findings from the Australian Positive and Peers Longevity Evaluation Study (APPLES). Sexual Health. 19(6). 533–545.

Bartlett, Sofia, Andrey Verich, Phillip Read, et al.. (2022). Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct‐acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort. Health Science Reports. 5(5). e719–e719. 1 indexed citations

Rockstroh, Jürgen K., Mark Nelson, Christine Katlama, et al.. (2015). Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The Lancet HIV. 2(8). e319–e327. 218 indexed citations

10.

Bardin, Thomas, Alexander So, Mark Bloch, et al.. (2012). Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT. IRIS. 4 indexed citations

11.

Schlesinger, Naomi, Rieke Alten, Thomas Bardin, et al.. (2012). Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Annals of the Rheumatic Diseases. 71(11). 1839–1848. 250 indexed citations

12.

Amin, Janaki, et al.. (2012). Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(5). 525–533. 31 indexed citations

13.

Martin, Allison, Janaki Amin, Sean Emery, et al.. (2011). Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE. 6(10). e26885–e26885. 14 indexed citations

14.

Calmy, Alexandra, Mark Bloch, Handan Wand, et al.. (2010). No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial^*. HIV Medicine. 11(8). 493–501. 21 indexed citations

15.

Martin, Allison, Mark Bloch, Janaki Amin, et al.. (2009). Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial. Clinical Infectious Diseases. 49(10). 1591–1601. 176 indexed citations

16.

Bodsworth, Neil, Mark Bloch, Anna McNulty, et al.. (2008). 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sexual Health. 5(3). 219–219. 17 indexed citations

17.

Winston, Alan, Mark Bloch, Andrew Carr, et al.. (2005). Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 56(2). 380–387. 42 indexed citations

18.

Leth, Frank van, Erik S.G. Stroes, Brian Gazzard, et al.. (2004). Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. PLoS Medicine. 1(1). e19–e19. 208 indexed citations

19.

Bodsworth, Neil, Mark Bloch, Mark Bower, David Donnell, & Richard C. Yocum. (2001). Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi??s Sarcoma. American Journal of Clinical Dermatology. 2(2). 77–87. 64 indexed citations

20.

Zutshi, D W, et al.. (1973). DOUBLE-BLIND CROSS-OVER STUDY OF ORUDIS AND PLACEBO IN FIFTY PATIENTS WITH RHEUMATOID ARTHRITIS. Lara D. Veeken. 12(2). 62–67. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact